Hereditary Angioedema Clinical Trial
— APeX-SOfficial title:
An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema
Verified date | May 2023 |
Source | BioCryst Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II Hereditary Angioedema (HAE).
Status | Completed |
Enrollment | 387 |
Est. completion date | April 27, 2022 |
Est. primary completion date | April 27, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Key Inclusion Criteria: - Subjects with HAE Type I or II who either have participated in a previous BCX7353 study or, in selected countries, in the opinion of the Investigator are expected to derive benefit from an oral treatment for the prevention of angioedema attacks. - Access to appropriate medication for treatment of acute attacks - Acceptable effective contraception - Written informed consent Key Exclusion Criteria: - Pregnancy or breast-feeding - Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study - Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study - Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior study - Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology - Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by the Sponsor or Investigator - Investigational drug exposure, other than BCX7353, within 30 days prior to the screening visit (or baseline if no screening visit) |
Country | Name | City | State |
---|---|---|---|
Australia | Study Center | Adelaide | |
Australia | Study Center | Campbelltown | |
Australia | Study Center | Camperdown | |
Australia | Study Center | Melbourne | |
Australia | Study Center | Murdoch | |
Australia | Study Center | Nedlands | |
Austria | Study Center | Graz | |
Austria | Study Center | Vienna | |
Denmark | Study Center | Odense | |
France | Study Center | Grenoble | |
France | Study Center | Lille | |
France | Study Center | Paris | |
Germany | Study Center | Berlin | |
Germany | Study Center | Frankfurt | |
Germany | Study Center | Ulm | |
Hong Kong | Study Center | Central | |
Hungary | Study Center | Budapest | |
Israel | Study Center | Ashkelon | |
Israel | Study Center | Haifa | |
Israel | Study Center | Tel Aviv | |
Israel | Study Center | Tel HaShomer | |
Italy | Study Center | Milan | |
Italy | Study Center | Padova | |
Italy | Study Center | Salerno | |
Korea, Republic of | Study Center | Daegu | |
Korea, Republic of | Study Center | Donggu | |
Korea, Republic of | Study Center | Gyeonggi-do | |
Korea, Republic of | Study Center | Seoul | |
New Zealand | Study Center | Auckland | |
New Zealand | Study Center | Wellington | |
North Macedonia | Study Center | Skopje | |
Poland | Study Center | Kraków | |
Serbia | Study Center | Belgrade | |
Serbia | Study Center | Niš | |
Slovakia | Study Center | Martin | |
South Africa | Study Center | Cape Town | |
Spain | Study Center | Barcelona | |
Spain | Study Center | Madrid | |
Switzerland | Study Center | Zürich | |
United Kingdom | Study center | Birmingham | |
United Kingdom | Study Center | Bristol | |
United Kingdom | Study Center | Cambridge | |
United Kingdom | Study Center | London | |
United Kingdom | Study Center | Plymouth | |
United Kingdom | Study Center | Southampton | |
United States | Study Center | Ann Arbor | Michigan |
United States | Study Center | Austin | Texas |
United States | Study Center | Bentonville | Arkansas |
United States | Study Center | Birmingham | Alabama |
United States | Study Center | Boston | Massachusetts |
United States | Study Center | Centennial | Colorado |
United States | Study Center | Charlotte | North Carolina |
United States | Study Center | Chevy Chase | Maryland |
United States | Study Center | Cincinnati | Ohio |
United States | Study Center | Clackamas | Oregon |
United States | Study Center | Colorado Springs | Colorado |
United States | Study Center | Columbus | Ohio |
United States | Study Center | Dallas | Texas |
United States | Study Center | Durham | North Carolina |
United States | Study Center | East Providence | Rhode Island |
United States | Study Center | Evansville | Indiana |
United States | Study Center | Grand Rapids | Michigan |
United States | Study Center | Greer | South Carolina |
United States | Study Center | Happy Valley | Oregon |
United States | Study Center | Hershey | Pennsylvania |
United States | Study Center | Indianapolis | Indiana |
United States | Study Center | Irving | Texas |
United States | Study Center | Lincoln | Nebraska |
United States | Study Center | Little Rock | Arkansas |
United States | Study Center | Louisville | Kentucky |
United States | Study Center | Madison | Mississippi |
United States | Study Center | Marietta | Georgia |
United States | Study Center | Milwaukee | Wisconsin |
United States | Study Center | Murray | Utah |
United States | Study Center | Normal | Illinois |
United States | Study Center | Overland Park | Kansas |
United States | Study Center | Rochester | Minnesota |
United States | Study Center | Saint Louis | Missouri |
United States | Study Center | San Antonio | Texas |
United States | Study Center | San Diego | California |
United States | Study Center | Scottsdale | Arizona |
United States | Study Center | Seattle | Washington |
United States | Study Center | Spokane | Washington |
United States | Study Center | Tampa | Florida |
United States | Study Center | Walnut Creek | California |
United States | Study Center | Waterbury | Connecticut |
United States | Study Center | Wheat Ridge | Colorado |
Lead Sponsor | Collaborator |
---|---|
BioCryst Pharmaceuticals |
United States, Australia, Austria, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, New Zealand, North Macedonia, Poland, Serbia, Slovakia, South Africa, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety & Tolerability | The number and percentage of subjects with treatment-emergent adverse events. | Up to 96 weeks (US) / 216 weeks (Rest of World (ROW)). | |
Secondary | Incidence of Acute Attacks of Angioedema in Subjects During Treatment | Number of 'adjusted' attacks were assessed. Adjusted attacks included at least 1 symptom of swelling, had a response of 'no' to the diary question, 'In retrospect, could there be an alternative explanation for your symptoms other than an HAE attack (i.e., allergic reaction, viral cold etc.)?', and were considered unique (attack began > 24 hours from the end of the prior attack). Any attack that began within 24 hours from the end of a prior attack was combined with the prior attack. | Up to 96 weeks (US) / 216 weeks (ROW) | |
Secondary | The Durability of Response to Treatment | To evaluate if the rate of attacks remains consistent (durable) over time, the monthly attack rate was assessed at 0 to 24 weeks, 24 to 48 weeks, 48 to 96 weeks and 96 weeks until the end of the study. Monthly attack rate was defined as the total number of adjusted HAE attacks experienced during the treatment period adjusted for the length of a month (defined as 28 days) and the number of days the subject was on treatment during that month. | Up to 96 weeks (US) / 216 weeks (ROW) | |
Secondary | Patient Reported Quality of Life (QoL) During Treatment | Quality of Life (QoL) specific to hereditary angioedema (HAE) was assessed at baseline and at each study visit until the end of the study. The questionnaire (i.e. AE-QoL) consisted of 17 questions spanning 4 domains (functioning, fatigue/mood, fear/shame, and nutrition). Each AE-QoL question had 5 answer options (scored 1-5), with lower and higher scores indicting less and more adverse impact, respectively. Per-subject scores for each domain were computed using the appropriate scoring algorithm applied to the question response scores for each domain. Per-subject total scores (including all 4 domains) were similarly computed using the question response scores for all 17 questions. The outputs from the scoring algorithm were normalized on a scale ranging from 0 (less adverse impact) to 100 (most adverse impact). The Mean change from baseline (CFB) in AE-QoL total score over time is presented below. | Up to 96 weeks (US) / 216 weeks (ROW) | |
Secondary | Patient's Satisfaction With Medication During Long Term Administration of Berotralstat | The Treatment Satisfaction Questionnaire for Medication (TSQM) was completed by subjects at baseline and at each study visit until the end of the study. TSQM scores consisted of 14 items of which 13 items were made up of 3 specific scales (Effectiveness, Side Effects, and Convenience) and 1 global satisfaction scale (Global Satisfaction). At baseline, TSQM questionnaires were completed based on subject's satisfaction with usual medications. At all other time points for collection of TSQM, subjects were asked about their level of satisfaction or dissatisfaction with the study drug. Scale scores were calculated for each scale and were transformed into scores ranging from 0 to 100, with higher scores indicating higher satisfaction. TSQM score and corresponding change from baseline values were calculated at each visit. Note: Subjects in Hong Kong did not complete the TSQM. | Up to 96 weeks (US) / 216 weeks (ROW) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06007677 -
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
|
Phase 2 | |
Completed |
NCT00997204 -
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
|
Phase 3 | |
Completed |
NCT00438815 -
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
|
Phase 3 | |
Completed |
NCT00748202 -
Berinert P Study of Subcutaneous Versus Intravenous Administration
|
Phase 3 | |
Completed |
NCT01426763 -
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
|
Phase 2 | |
Terminated |
NCT04091113 -
Hereditary Angioedema Kininogen Assay
|
||
Completed |
NCT00432510 -
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
|
Phase 1 | |
Completed |
NCT03712228 -
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
|
Phase 2 | |
Active, not recruiting |
NCT05453968 -
Berotralstat Treatment in Children With Hereditary Angioedema
|
Phase 3 | |
Recruiting |
NCT05511922 -
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
|
Phase 3 | |
Recruiting |
NCT05505916 -
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
|
Phase 3 | |
Not yet recruiting |
NCT02159430 -
Hereditary AngioEdema, Neurobiology and Psychopathology
|
N/A | |
Completed |
NCT02303626 -
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
|
Phase 2/Phase 3 | |
Completed |
NCT01984788 -
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
|
Phase 2 | |
Completed |
NCT04888650 -
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
|
||
Completed |
NCT02448264 -
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
|
Phase 1 | |
Completed |
NCT05118958 -
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
|
Phase 1 | |
Completed |
NCT06414252 -
Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
|
||
Active, not recruiting |
NCT04739059 -
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
|
Phase 3 | |
Completed |
NCT02819102 -
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
|
Phase 1 |